Principal objective is to identify biomarkers of phenotypes in asthma patients who are expected to benefit, or not benefit, from treatment with the MedImmune immuno therapeutic drug benralizumab (formerly MEDI-563)

  • Kurosky, Alexander, (PI)

Project: Other project

StatusFinished
Effective start/end date4/1/123/31/17

Funding

  • MedImmune, Inc.: $1,126,301.00